Through discovery, innovation and collaboration, researchers at the Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta are investigating safer, less toxic and more effective methods of treatment for children with cancer. Program themes include:
- Aberrant signaling nodes
- Novel drugs and combinations
Clinical and Translational Research
- The NanoPro 1000 system (cell biosciences) enables a rapid and quantitative analysis of specific proteins from as few as 25 cells per sample. Drs. Kevin Bunting and Himalee Sabnis, along with a senior research technician Heath Bradley, use the automated, capillary based immunoassay platform to obtain precise and quantitative data of the phosphorylation states of proteins separated by isoelectric focusing. The instrument is capable of analyzing dozens of different proteins within a single sample or it can analyze a single protein in up to 96 samples per run. The group is developing assays for profiling of signaling pathways in valuable patient samples.
mTOR targeted therapies
Drs. Frank Keller (ALL) and Kevin Bunting and Himalee Sabnis (AML) are focused on effectively inhibiting the mTOR pathway using innovative approaches in combination with rapamycin which alone is not very effective at suppressing protein synthesis downstream of a highly activated PI3K/AKT/mTOR pathway.
Clinical and Translational Researchers